Smoking History and Response to Nivolumab in Patients with Advanced Nsclcs
Matthew D. Hellmann(AstraZeneca (United States)), Naiyer A. Rizvi(Synthego (United States)), Wade T. Iams(Vanderbilt University Medical Center), Julie R. Brahmer(Johns Hopkins University), Scott Antonia(Parker Institute for Cancer Immunotherapy), Kaitlin M. Woo(Cornell University), Ben Creelan(Moffitt Cancer Center), Scott Gettinger(Yale Cancer Center), Camelia S. Sima(Memorial Sloan Kettering Cancer Center), Leora Horn(Heidelberg University), Christopher Harbison(Bristol-Myers Squibb (Germany))
Cited by 32
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k